EXPIRES
`
`3-SE 1998 BSDS
`mr_ TIPl.E SCLEROSIS
`
`BOSTON SPA
`L 23 780
`
`• C
`
`ART 4
`
`
`
`
`
`
`
`Sawai (IPR2019-00789), Ex. 1044, p. 001
`
`

`

`Multiple
`Sclerosis
`
`Editor-in-Chief:
`Ingrid V Allen Belfast, UK
`
`Co-Editor' for lhe Americas:
`Donald H Silberberg Philadelphia, USA
`
`Co-Etlilor for Asia-Pacific:
`Takahiko Saida Kyoto, Ja.pan
`
`Editorial Board:
`
`J Abbott UK
`0 Abramsky l.srael
`DW Anderson USA
`JP Anlcl Canada
`D Bales UK
`WF Blakemore UK
`L Cuznor UK
`DAS Compston llK
`CC Ehors Canada
`M Feldman UK
`RS Fujinami USA
`RI Grossman USA
`JF Hallpiko Auslrali;i
`S Hauser USA
`SA Hawkins UK
`OR Hommos Thu Netherlands
`MW Hutchinson Irclancl
`KP Johnson US/\
`PGE Kennedy UK
`I Kirk llK 1
`1-1 Lassmann Auslrin
`
`L L:1yward UK
`C Lubetzki France
`FD -Lublin USA
`S Ludwin Canada
`WI McDonald UK
`HF McFarland USA
`OW Paly Canacl11
`DE Pleasure USA 2
`I Princas USA
`M Raff UK
`CS Raine USA
`S Reingold USA
`L Steinman USA
`INW Tourlollolle USA
`H deF Webster USA
`H Wekorlo Gcmmny
`JS Wolinskv USA
`I-IL Weiner USA
`JN Whitaker USA
`Y Yonezawa Japan
`
`1DP.puty ndilur. Europn
`
`2 Dopuly oclilor. the Americas
`
`~
`STOCKTON
`
`Sawai (IPR2019-00789), Ex. 1044, p. 002
`
`

`

`Journals now publi hed
`tockton
`by
`British Homeopathic Journal
`Drug Stability
`European Journal of Human
`Genetics
`Molecular Oncology
`• Tumor Targeting
`• Twin Research
`
`WORLD WIDE WEB SITE
`http:/}www.stockton·press.co.uk
`
`Visit the Stockton online
`where the Table of Contents
`and Abstracts for all these
`journals are available FREE on .
`the day of publication;
`
`For further information on all these
`journals, please contact
`Sharon Marshall, Stockton Press,
`Houndmills, Basingstoke, RGZl 6XS, UK.
`Tel: +44 (OJ 1256 351898
`Fax: +44 (0) 1256 328339
`E-Mail: s.marshall@stockton-press.co.uk
`OR, in North America:
`Stockton Press, DepL J, 345 Park Avenue
`South, New York 10010-1707 USA.
`USA Toll Free Number: + 1 800 747 3187
`
`An International Pubt~her_
`
`Sawai (IPR2019-00789), Ex. 1044, p. 003
`
`

`

`98
`E C T R
`MS
`
`I •
`
`: , p c:
`L._ . - ----... -. .... llllllliiill_•_._-__ -
`
`I
`... ,
`
`14th Congress of the European
`Committee for Treatment and Research in Multiple Sclerosis
`Stockholm, Sweden, September 9-12, 1998
`
`Local Organising Committee
`
`ECTRIMS Executive Committee
`
`Hans Link (Chairman)
`Jan Hillert (Scientific Secretary)
`Magnus Andersson
`Moiz Bakhiet
`Sten Fredrikson
`Kristina Gottberg
`Tomas Olsson
`Anders Svenningsson
`
`Ji.irg Kesselring (President)
`Christian Confavreux
`(V ice-President)
`Alan Thompson (Secretary)
`Luigi Amaducci
`Reinhard Hohlfeld
`Chris Pol.man
`Per Soelberg-Sorensen
`
`Congress Secretariat
`
`Congrex Sweden AB
`Attn: ECTRIMS '98
`PO Box 5619
`SE-114 86 Stockholm, Sweden
`Tel: +46-8-459 66 oo
`Fax: +46-8-661 91 25
`E-mail: ms@congrex.se
`
`Congress Home Page
`
`http ://v-.rww.congrex.com/ ectrims98/
`
`Sawai (IPR2019-00789), Ex. 1044, p. 004
`
`

`

`~ CKIDN
`
`Multiple Sclerosis is published by Stockton Press, a division of
`Macmillan Press Ltd .
`
`Scope Multiple Sc/P.rosis is publis.hed bimonthly. The journal
`focuses on the aetiology and pathogenesis of demyelinaLing and
`inflammalory diseases of the r.enlral nervous system. II also deals
`with the application of these studies lo scientifically based
`therapy.
`
`is covered by BIOSIS/Current Awareness
`journal
`This
`in
`lliologic:al Scienc:es, CURRENT CO TENTS EMBASE/Excerpta
`Medica. and MEDLINE
`
`Editorial Manus<:ripls and all editorial r:orrespondence should
`bn sent lo:
`Ingrid V Allen
`Editor in Chief
`Rr.s,,arch and Devclopmr.nl Office, Champion House.
`1 :l-22 Linenhall Stroot. Belfasl BT2 8BS. UK
`Toi +44 (OJ 12:12 !153617: Fox +44 (OJ 1232 553674
`Donald H Silberberg
`Co-Edi/or for the Am11ric:a.~
`Deparlmen t of N1mrology. Universily of Pr.nnsylvania.
`Medic:al Center. 1007 Blackley Hall, 423 Guardian Drive.
`Philadelphia PA 19104-6021, USA
`Tel + 1 215 1198 0283; Fax + 1 it 5 li62 :i:153
`
`Takahido Saida
`Co-Editor for /\sia-Par:ifir:
`Dtiparlmcnl of Neurology. Utano Nalional Hospital.
`Kyolo 616D, Japan
`·fol +111 75 461 5121; Fax +81 75 464 0027
`Advertisements Enquiries concerning advertisements should be
`arldrnssed lo: Alison Reeves, Aclverlisemenl Co-ordinator, Stock(cid:173)
`ton Prr.ss, Houndmills. Basingstoke. Hampshire. RG21 6XS, UK.
`Td: 01256 :102622. Fax: 01256 :128339.
`Publisher /\II busim:ss correspondem:e , supplemenl enquiries
`and reprinl requesls should be addressed lo Multiple Sclerosis.
`Stockton Prnss, Hounclmills. Basingstoke, Hampshire. HG21 6XS.
`UK. Tel: +44 [OJ 1256 329242, Fax: +44 (tl) 1256 810526.
`Publishe.r: Milrija Vukovojac
`Produclion Controller: Debbie Cole
`Supplemm1t Production C:onlroller: Nicci Crawley
`WWW Multiple Sc/ernsis is on the lnlernel at
`hltp://www.stockton-press.co.uk
`All informalion on the websi le is free and includes editor's
`details. sc:ope. lnte.~I Uthle nf conlenls. subscription prices, reprinl
`ordering. sample copy ordering. news. supplement information,
`c;ontac:I names in publishing. production, marketing and adver(cid:173)
`ti~ing departmonls. Rngisler now to havo tho lablo of conlr.nli;
`sent to you as soon as tlu:y are updaled.
`
`Subscrip tions:
`1998 SubscriptiO!l RH lt!s - Multiple Sclerosis
`
`rNSTITUTIONAL SUBSCRIPTIONS
`Print [Hard copy)
`EU
`Rest of World (surface mail)
`Rest of World (airmail)
`Electronic - Online only
`Combined - Electronic Online & Print
`EIJ
`Rest or World (surface mail)
`R(!st of World (aiimail)
`
`£170
`£186/S300
`£224/S360
`£170/$275
`
`£187
`£205/£330
`£246/$395
`
`PERSONAL SUBSCRIPT IONS
`Print (Hard copy)
`EU
`Rest of World (surface mail)
`Rest of World (airmail)
`Electronic - Online only
`Combined - Electronic Online & Print
`EU
`Resl of World (surface mai l)
`Rest of World (airmail)
`
`£81
`£81/$125
`£119/$185
`£81/$125
`
`£89
`£89/$135
`£130/$199
`
`Subscriptions - Outside the USA
`Orders musl br. accompanied by re mi ttance. Cheques should be
`made payable to Macmillan Journals Subscriptions Ltd and sent
`to: The Subscriplion Department, Macmillan Press Lt<l, Hound(cid:173)
`mills, Basingstoke, Hampshire RG21 6XS, UK. Where appro(cid:173)
`priate. subscribers may make payments into UK Post Office Giro
`.Account No: 519 2455. Full details must accompany the
`payment.
`
`Subscrip tions - USA
`USA subscribers can call toll free: 1 800 747 3187. Please send
`check/mone
`order/credil card de lails
`to: T he Subscription
`Department, Macmillan Press Ltd, Houndmills, Basingstoke,
`Hampshire, RG2 t OXS, UK.
`
`Prices arn set in UK sterling. Dollar prices aro converted from UK
`slerling at the current exchange rate. Accordingly, your credit
`card charge may vary slightly from lhe Dollar rale shown. To
`obtain lhe exact Dollar ra te shown, please rem it by c heck. All
`prices, spec:ificalions and details are subjecl to change without
`prior notification.
`
`Multiple Sclerosis (ISSN 1352 4585) is published bimonthly by
`Macmillan Press Ltd, c/o Mercury Ai rfreight International Ltd,
`2323 Randolph Avenue, Avenel , NJ 07001. USA. Subscription
`price per institution is $255 per annum (surface). Application to
`mail at Periodicals Postage Rate is pending at Rahway NJ: send
`acldress corrcclions to Macmillan Press Ltd. c:/o Mercury Air(cid:173)
`freigh t International Ltd, 2323 Randolph Ave nue, Avonel NJ
`07001.
`
`Reprints of any article in this journal are available from Slocklon
`Press, Hmmdinills, Basingstoke. Hampshire RG2 1 6XS, UK. Tel:
`+44 (0) 1256 329242. Fax: +44 (0) 1256 810526.
`Copyright © 1998 Stoc kton Press
`ISSN 1352 4585
`
`All righls of reproduction are reserved in respect of all papers,
`in
`this
`journal
`in all
`illustrations. etc., published
`articles,
`countries of the world.
`
`All materiaJ published in th is journal is protecled by copyright,
`which covers exclusive rights to reproduce a nd distribute the
`material.
`o material published
`in
`lhis
`journal may be
`reproduced or stored on microfilm or in electronic, o ptical or
`magnetic form without the written authorisatio n of the Publisher.
`
`Authorisation to pholocopy iiems for internal or personal use of
`specific clients, is granted hy Stockton Press for libraries and
`other users registered with the Copyright Clearance Centre (CCC)
`Transaction Reporling Service, provided that the base fee of
`S1 i.oo per copy is paid directly to CC:C, 21 Congress St, Salem,
`MA 01970, USA 0031-1758/98 S12.00 + $0.00.
`
`Aparl from any fair deali ng for the purposes of research or
`private study. or criticism or review. as permitted under the
`Copyright, Designs and Patent Act 1988, this publication may be
`reprod uced, stored or lransmitled, in any form or by any means.
`only wi th the prior permission in writing of the publishers, or in
`the case of reprographic reproduction. in accordance wilh lhe
`tenns of licences issued hy the Copyright Licensing Agency.
`
`Whilst ovmy r.lTor1 i., marlre hy lhc publishms and oclilorial bunrcl lo sec 1ha1 no inaccuro1e or mislr.ilding dala, opinion or h1alomonl appears
`in lhis journal. llwy wish lo make ii r:lcar lhal lhe rlata anrl opinions appnaring in lhe arlides anrl acfverlisr.mcnls herein are· 1hr.
`,.._,punsihilily of the con1rib11lor or ndvllrlisr.r r.oncerncd. Aci:ordin~ly. lhe puhlishers. the l.'dilorial commillcc nnd !heir rc.spcclivc
`cmployt!es. offii:r.r.s and oi;cnls acc:cpt no liahility whatsncv<:r for 1he consequences of any sut:h inar.1:urale or misleading dala. opinion or
`Slalcmr.nL Whilst Hvery c~fnrl is _modi: to Hnsure Iha! drug dns~.s ,mil ollmr quanl!lics are pri:sentcd accurnlr.ly. renders Arc advisArl lhal new
`methocls and tr,chn,qur.s mvolvmg drui; nsagr., and de.scribed within !his journal. should only be followed in mnjunclion wi th llm drug
`manufnc:h1n,r's own published li1ural urc.
`
`Ty(ll".set hy li:litc Typesetting Techniques , Eastl.eigh, Hanis
`Printed on acid-free papc,r, i,lfor.live with Volume 1, Issue 1 . 1!195
`Prinlterl an<t bound by The Friary Press. Dorchcsl<:r, Dorset
`
`Sawai (IPR2019-00789), Ex. 1044, p. 005
`
`

`

`c eros1s
`
`CLINICAL AND LABORATORY RESEARCH
`
`Volume 4 • Number 4 • August 1998
`
`9 September 1998
`DB
`MS Database
`
`10 September 1998
`OR I
`Pathology and Genetics
`Management and euroimaging
`lmmunology
`Neuropathology and Biochemistry of MS
`SI
`New Trends in MS Rehabilitation
`WI
`Update on Neuroimaging
`S2
`Animal models - their Usefulness in MS
`W2
`Poster Se.~ion !
`PI
`ARTI Regulation and Execution of Apoptotic Cell Death
`
`11 September 1998
`OR2
`Immunology
`Treatments
`CSF, other
`The New Immunology of MS
`The MS Clinic: Organisation and Clinical
`Man_agement
`Genetic Susceptibility: How to Proceed?
`CSF in MS
`Poster Session 2
`
`S4
`W4
`P2
`
`S3
`W3
`
`12 September 1998
`S5
`New/Improved MS Treatments
`P3
`Poster Session 3
`S6
`European MS Research al the Tum of the Millennium:
`Strenglhs and Weaknesses
`Author Index
`
`Ab tracl Numbers
`
`Page Numbers
`
`DB1 - DB3
`
`ORIOI-ORI06
`ORI07-0RI 12
`OR I 13-0RI 18
`SIOI-Sl03
`W\OI - Wl05
`S20l-S203
`W201- W203
`PI OOI-PI 142
`ARTIOI
`
`OR201-0R206
`OR207-0R2 I 2
`OR213-0R2 I 7
`S301-S302
`W301-W304
`
`S401
`W401-W403
`P2001 - P2149
`
`S501-S502
`P3001-P3069
`S601-S603
`
`271
`
`272
`274
`276
`278
`279
`281
`282
`284
`322
`
`323
`325
`327
`329
`330
`
`331
`332
`333
`
`373
`374
`393
`
`394
`
`DB - MS Databasees
`OR - Oral Presentation
`S - Major Symposium
`
`W - Educational Workshop
`P - Poster
`ART - State of Che Art Lecture
`
`~
`STOC KTON
`
`TI1e contents page of this journal is now a,·ailable on the
`Internet at: http://www.stockton-press.co.uk
`
`Sawai (IPR2019-00789), Ex. 1044, p. 006
`
`

`

`384
`
`Ectrims 98
`
`P3037
`Monitoring rrcalmffll •ffiriacy with magortic resonance
`imaging (MRI) in an open phase II study with oral fumaric(cid:173)
`acid e.,lers (l"umaderm") in poti.cnu wil.b rtl:ipsing-rcmilliag
`MS(RRMS)
`Meier D. Schimrigk S. Brune N. Hollinann V, Pohlau D, Pr7.untcl
`II, Oepanmcnl
`of Neurology,
`Josef-Hospital
`St.
`Unive!Sil~tskfinilc Bochum. Germany
`Background: MRI has become a powerful in.strurnenl for
`Multiple Sclerosis {MS) trial moni1oring as a surrog,,lc parameter
`of di.scase activity. In this S1udy we pcrfonn multiple MRI in 8
`paticnls with def: KRMS under oral fumaric-acid esters therapy
`ro, a period of 18 week.~
`1aterlab and Mc!hods: For study evnluolion we carry out
`immediate before
`baseline MRI scans 6 ww:eks before and
`1rca1men1. Also in 1he treatment period 12 and 18 weeks after firs!
`dose of study mcdiculion. Each time we perform conventiolllil T, ·
`weighted {TR~)300 ms. 'fl!"'90 ms). triple dose gadolinium(cid:173)
`DTI'/\ enhanced T,-wcighted CTR=800 n~<, TEcl7 m<) and nati,,.,
`T,-wcighlL-d MRI (44 contiguous intc:rlcavcd. 3 mm slices eacli.
`spatial resolut ion less 1han I mm). MRI are aequin:d on a 2 Tc:sb
`Bruker Tomikon scaMer. Image data arc direelly carried over into
`the image processing software. We use cu,,tom-made Image Toor"
`scripts for scrni-outomalcd image data utilisation. Main outcome is
`in
`rhc reduction of the number or ac1ivc
`lesions detected
`gadolinium enhanced T,-wcightcd MRI under 1rea1nienl compaml
`10 b:lreline. In additiorl the 101al lesion loll.d will be measured from
`Tr weigh1ed MRI.
`Results: So Car not all p3.ticn1s hnve finished the study. Our fim
`f\'Suhs urc very ,;n~Quraging, showing a dclinirivc decline of 1h<
`g:,Jolinium enhancing fc:sion number under treatment in each of
`the fir~t four study patients with RRMS indicating a possible
`1n,auncn1 ~rr-.ciacy or oral rumaric-acid esters in rhc rherapy or
`MS.
`
`P3039
`Inhibition ofTNF-« in relapsing MS increases clinical relapses
`
`The Lcncrccp1 MS Study Group, presented by G.S. Francis'
`1Montrc•I Neurological Institute, Montreal, Canada
`
`theoretical concepts and animal
`Background: Based on
`expcrimcnral evidence, there exists support for a role for pro(cid:173)
`infiammarory cytokincs in multiple sclerosis (MS) lesion
`pathogenesis. Administration of compounds 10 counteract pro(cid:173)
`inflammatory cytokines holds promise as tllcrapy in MS. We
`rq>ort the r~llS of blocking TN Fa in relapsing MS.
`
`Methods: 168 definite relapsing MS patients were treated in a 4
`anm {3 doses, I placebo) double-blind study of a recombinant
`rusion protein {TNF receptor JgG fusion protein). Patients
`received monthlydosing(IO mg, SO mg, JOO mg or placebo) for
`up to 48 weeks. Clinical assessments occurred every mon1h
`wltilc MRJ scans with and without gadolinium were perfonned
`al -4, 0, 4. 8, 12, 16, 20 and 24 weeks.
`
`Results: Relapse rate increased in patients taking TNFa inhibitor
`as compared to placebo: annualized relapse rate placebo = .98,
`10 mg = 1.00, SO mg "' 1.64, 100 mg"' 1.47 ()V'.009). A trend
`was also seen for prolonged relapse duration, increased relapse
`severity and incre:is<d MRJ activity wirh lrcatmenL Non(cid:173)
`neutralizing antibodies were seen in almost all trc:itcd patients
`but did not affect relapse frequency.
`
`~onclusion: Although cytokine manipulation holds promise, the
`!mpact of any manipulation may vary depending on the state or
`immune activation being targeted.
`
`P3038
`Dcledion ofalltnd ialracellularTH,· ~nd TH2-typc cytoklae
`produdion or peripheral blood 111ononucle1r cells (PBMCs) in
`palienu wirb relapsiug-remittlag Multiple Sckro,i, (RR :tS)
`oadergoiog •o oral fumaric-acld utu tbenpy
`Brune N, Schimrigk S, Meier D, Jocks M, Hoftin.'.lnn V, POhlau
`D, Przwnek H, Department or Neurology, Sl. Josef-HospitaJ,
`Universitllsldinik Bocbum, Germany
`inflanunatory
`is an
`Background: Multiple Sclerosis {MS)
`dcmyclinating autoimmwic-diSt:asc of the central nervous system.
`Relapses in MS arc assumed to be mediated by a TH,-type
`e)'lokinc proftlc whereas remissions are correlated with a TH2·
`type cytolcine pallem. We investigate the influence of oral
`fumaric..ecid cS1ers (Fun,pdenn•) as a possi'ble treatment for
`patients with RRMS during an open phase 11 prospective study.
`Materials 1111d Mtlhods: We C)(amincd 8 palienlS with defrnitivc
`RRMS. The investigation over 2ll wetk$ is divided into a baseline
`section (6 weeks), a treatment period (18 weeks) and a poSl·sludy
`section (4 weeks). Sevcml times ""' detect intracellular cytokioe
`production of PBMCs by flow c)'lomcuy. Using this technique,
`we measure the percentage of TH, 01.-2, TNF-a, INF-y)-and TH2
`(IL-4, 11..-10, TGF-ll)·lypc cytokines and their modification under
`drug therapy. Additionally we analyze the serum levels or soluble
`intracellular adhesion molecule I (slCAM l) by ELISA.
`RosuJL,: Until now, nol all paticnls finished the complete study.
`find a significant
`Under oral funwic-ac id esters lhctapy Wte
`inercase of TH,-!~ cytokincs regarding 11.-4. IL-IO ond TGF·P
`compan:d lo ba.sclinc. The findings persist during the trClllment
`period and decline nearly to the mscline data at the post study
`KC!iQn, Tiff-a. in,ri:= under lhcfUl)y which is propnbly related
`to the rise orJL-10. The main influence offumaric-acid esters on
`TH,·t)PC cytokines in patients with RRMS give this substance the
`porcncy 10 be n new oral drug therapy rhat could influence disease
`activity in MS.
`
`P3040
`Expanded Di.sability Status Scale (EDSS) dependend course of
`Multiple Sclerosis (MS): influence for clinical trials?
`
`Merke!bach S, Kohler A, MOiier M. Kolmel C, Scbimrigk K
`Department of Neurology, Homburg/Saar, Germany
`
`Background: Clinical trials proofed the efficiacy of modem
`drugs in the treatment of relapsing-remitting MS. Howeyer,
`nearly all trials used different inclusion criteria especially with
`· regard to EDSS limits.
`Patients and methods; We studied the long-term courses of300
`unselected patients (67% women, 33% men; mixed ambulatory
`and hospital series) retrospectively assessing the EDSS and
`calculated lht changes from visit to visit. Mean variation for
`relapsing-remitting patients with EDSS from O to 3.5 (group I)
`was compared 10 patients with EDSS &om O to 6.0 (group ff).
`Results: S6% of the patients were categorized as relapsing·
`remiuing MS (mean age at onset 2&.5 years, mean duration of
`disease 10.1 ys), 25% were secondary progressive (age 30.4 ys.
`duration 17.S ys), 19"/o were prirruuy progrcssive(age 36.6 ys,
`duration 12.8 ys). ln group I patients, the mean EDSS increase
`between consecutive visits was 0.24± 1.21 (mean intuvaU of
`visits I. 74 ys) and was significantly higher as compared to
`group U p1ticn1s with EDSS increase of0.11:1.26 (mean
`intervall 1.S8 ys; p < O.OS for EDSS change).
`Conclusion: Our data confirm the evidence, that results of
`clinical trials such as went of improvement, stability or
`worsening depend on the selection of patients with spccilll
`respect to non-linear EDSS-steps. Thus, for comparison or
`therapeutical efficiency between different trials uniform EDSS
`inclusion criteria arc needed. at least for relapsing-remining MS.
`
`Sawai (IPR2019-00789), Ex. 1044, p. 007
`
`